FAM
SNDX icon

Fred Alger Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Fred Alger Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,977
Closed -$381K – 562
2022
Q4 		$381K Buy
14,977
+1,359
+10% +$31.7K ﹤0.01% 412
2022
Q3 		$327K Buy
+13,618
New +$306K ﹤0.01% 413

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fred Alger Management's SNDX Position: Q1 2023 in Review

Fred Alger Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 14,977 shares — an estimated $381K sold.

Fred Alger Management first reported a position in SNDX in Q3 2022 and held it in 2 quarters. The position peaked at $381K in Q4 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Fred Alger Management reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Fred Alger Management sold 14,977 Syndax Pharmaceuticals shares in Q1 2023, an estimated $381K.
  • Fred Alger Management first reported a position in Syndax Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Fred Alger Management's Syndax Pharmaceuticals position peaked at $381K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Fred Alger Management's 13F filing for Q1 2023, filed 15 May 2023.